Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros












Base de dados
Intervalo de ano de publicação
1.
Zhonghua Er Ke Za Zhi ; 56(4): 274-278, 2018 Apr 02.
Artigo em Chinês | MEDLINE | ID: mdl-29614567

RESUMO

Objective: To investigate the predictive factors of mortality in extremely preterm infants. Methods: The retrospective case-control study was accomplished in the Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University. A total of 268 extremely preterm infants seen from January 1, 1999 to December 31, 2015 were divided into survival group (192 cases) and death group (76 cases). The potential predictive factors of mortality were identified by univariate analysis, and then analyzed by multivariate unconditional Logistic regression analysis. The mortality and predictive factors were also compared between two time periods, which were January 1, 1999 to December 31, 2007 (65 cases) and January 1, 2008 to December 31, 2015 (203 cases). Results: The median gestational age (GA) of extremely preterm infants was 27 weeks (23+3-27+6 weeks). The mortality was higher in infants with GA of 25-<26 weeks (OR=2.659, 95% CI: 1.211-5.840) and<25 weeks (OR=10.029, 95% CI: 3.266-30.792) compared to that in infants with GA> 26 weeks. From January 1, 2008 to December 31, 2015, the number of extremely preterm infants was increased significantly compared to the previous 9 years, while the mortality decreased significantly (OR=0.490, 95% CI: 0.272-0.884). Multivariate unconditional Logistic regression analysis showed that GA below 25 weeks (OR=6.033, 95% CI: 1.393-26.133), lower birth weight (OR=0.997, 95% CI: 0.995-1.000), stage Ⅲ necrotizing enterocolitis (NEC) (OR=15.907, 95% CI: 3.613-70.033), grade Ⅰ and Ⅱ intraventricular hemorrhage (IVH) (OR=0.260, 95% CI: 0.117-0.575) and dependence on invasive mechanical ventilation (OR=3.630, 95% CI: 1.111-11.867) were predictive factors of mortality in extremely preterm infants. Conclusions: GA below 25 weeks, lower birth weight, stage Ⅲ NEC and dependence on invasive mechanical ventilation are risk factors of mortality in extremely preterm infants. But grade ⅠandⅡ IVH is protective factor.


Assuntos
Hemorragia Cerebral/mortalidade , Enterocolite Necrosante/mortalidade , Lactente Extremamente Prematuro , Doenças do Recém-Nascido/mortalidade , Peso ao Nascer , Estudos de Casos e Controles , Idade Gestacional , Humanos , Lactente , Mortalidade Infantil , Recém-Nascido , Recém-Nascido Prematuro , Modelos Logísticos , Estudos Retrospectivos , Fatores de Risco
2.
Lab Anim ; 47(2): 116-21, 2013 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-23492514

RESUMO

Mouse parvoviruses are among the most prevalent infectious pathogens in contemporary mouse colonies. To improve the efficiency of routine screening for mouse parvovirus infections, a multiplex polymerase chain reaction (PCR) assay targeting the VP gene was developed. The assay detected minute virus of mice (MVM), mouse parvovirus (MPV) and a mouse housekeeping gene (α-actin) and was able to specifically detect MVM and MPV at levels as low as 50 copies. Co-infection with the two viruses with up to 200-fold differences in viral concentrations can easily be detected. The multiplex PCR assay developed here could be a useful tool for monitoring mouse health and the viral contamination of biological materials.


Assuntos
Camundongos , Reação em Cadeia da Polimerase Multiplex/métodos , Infecções por Parvoviridae/diagnóstico , Parvovirus/isolamento & purificação , Doenças dos Roedores/diagnóstico , Actinas/genética , Actinas/metabolismo , Animais , Vírus Miúdo do Camundongo/genética , Vírus Miúdo do Camundongo/isolamento & purificação , Vírus Miúdo do Camundongo/metabolismo , Infecções por Parvoviridae/virologia , Parvovirus/genética , Parvovirus/metabolismo , Doenças dos Roedores/virologia , Sensibilidade e Especificidade , Análise de Sequência de DNA , Proteínas Virais/genética , Proteínas Virais/metabolismo
3.
J Thromb Haemost ; 9(7): 1318-25, 2011 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-21535390

RESUMO

BACKGROUND: The number of spinal fusion operations in the USA is rapidly rising, but little is known about optimal venous thromboembolism prophylaxis after spinal surgery. OBJECTIVES: To examine the use of and outcomes associated with venous thromboembolism prophylaxis after spinal fusion surgery in a cohort of 244 US hospitals. PATIENTS/METHODS: We identified all patients with a principal procedure code for spinal fusion surgery in hospitals participating in the Premier Perspective database from 2003 to 2005, and searched for receipt of pharmacologic prophylaxis (subcutaneous unfractionated heparin, low molecular weight heparin, or fondaparinux) and/or mechanical prophylaxis (compression devices and elastic stockings) within the first 7 days after surgery. We also searched for discharge diagnosis codes for venous thromboembolism and postoperative hemorrhage during the index hospitalization and within 30 days after surgery. RESULTS: Among 80,183 spinal fusions performed during the time period, cervical fusions were the most common (49.0%), followed by lumbar fusions (47.8%). Thromboembolism prophylaxis was administered to 60.6% of patients within the first week postoperatively, with the most frequent form being mechanical prophylaxis alone (47.6%). Of the 244 hospitals, 26.2% provided prophylaxis to ≥ 90% of their patients undergoing spinal fusion; however, 33.2% provided prophylaxis to fewer than 50% of their patients. The rate of diagnosed venous thromboembolism within 30 days after surgery was 0.45%, and the rate of postoperative hemorrhage was 1.1%. CONCLUSIONS: Substantial variation exists in the use of thromboembolism prophylaxis after spinal fusion surgery in the USA. Nevertheless, overall rates of diagnosed thromboembolism after spinal fusion appear to be low.


Assuntos
Quimioprevenção/métodos , Fusão Vertebral/efeitos adversos , Tromboembolia Venosa/prevenção & controle , Adulto , Idoso , Estudos de Coortes , Bases de Dados Factuais , Feminino , Fondaparinux , Hemorragia , Heparina/uso terapêutico , Humanos , Masculino , Pessoa de Meia-Idade , Polissacarídeos/uso terapêutico , Complicações Pós-Operatórias/prevenção & controle , Estudos Retrospectivos , Fusão Vertebral/métodos , Fusão Vertebral/estatística & dados numéricos , Meias de Compressão/estatística & dados numéricos , Resultado do Tratamento , Tromboembolia Venosa/etiologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...